Town's 10-year plan to deal with population growth
Thousands of jobs are expected to be created in Barrow, Cumbria, after the town was recognised as a strategic national asset because of its importance as a manufacturing base for Royal Navy submarines.
The new Plan for Barrow aims to transform the town so it can meet a rise in population while also improving housing and economic growth, the partnership behind the scheme said.
Team Barrow chief executive Peter Anstiss said a number of "long-standing issues" needed to be addressed to achieve a positive future .
Most of the jobs are expected to be created at submarine manufacturer BAE Systems, which was recently commissioned to build 12 attack submarines.
Mr Anstiss said the aim of the plan was to provide "improved housing and transport infrastructure, while also addressing social and health inequalities, to ensure everyone can connect to the opportunities in Barrow".
"We know these are the areas which the community and future residents will want to see tackled and that's why we've prioritised them in our plan," he said.
The decade-long strategy has been developed by Team Barrow, a partnership between the government, Westmorland and Furness Council and BAE Systems.
The projected has been supported by £220m of government investment.
One of its main focuses will be on transforming Barrow town centre into a "thriving" area, with more housing, retail and leisure facilities.
A previous plan for the town centre, led by Westmorland and Furness Council, has been shelved in favour of developing "a more ambitious programme of work".
Under the new scheme, housing in the town centre would be higher-density and include more rented properties to appeal to students and young people.
It also aims to build on Barrow's existing arts and culture sector, while providing support for businesses to grow.
"This is a long-term programme and we're confident that we have a plan and a vision that will match the ambitions of the community and deliver lasting benefits for generations to come," Mr Anstiss said.
A drop in session is being held on 10 July and 19 July at The Bridge, in Portland Walk, for members of the public to find out more about the Plan for Barrow.
Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.
Nuclear submarine port to be granted royal title
Submarine builds to bring 'prosperity to Barrow'
The Plan for Barrow
Westmorland and Furness Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Diageo plc (DEO) Announces Completion of Sale of Its Shareholding in Seychelles Breweries Limited
Diageo plc (NYSE:DEO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On July 1st, Diageo plc (NYSE:DEO) announced the completion of its sale of shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited. Diageo plc (NYSE:DEO) completed the sale of its 54.4% shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited, which is a subsidiary of Mauritius-based IBL Group, for approximately $80 million. The transaction was announced on April 2, 2025. The deal reflects the company's strategic move to focus on its portfolio management and high-margin brands while maintaining a strong presence in the Indian Ocean region through licensing agreements. A close-up of bottles of whisky and other alcoholic beverages from a winery. Under the terms of the deal, although Diageo plc (NYSE:DEO) has sold its majority stake, it retains ownership of its key brands produced by Seychelles Breweries, such as Guinness and Smirnoff RTDs. These brands will continue to be produced and distributed in Seychelles under new long-term license and royalty agreements with Seychelles Breweries, ensuring ongoing collaboration. Diageo plc (NYSE:DEO) is a UK-based producer and distributor of premium alcoholic beverages. The company operates a vast portfolio of brands and has a presence in 180 countries. While we acknowledge the potential of DEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on
Yahoo
4 hours ago
- Yahoo
£10k to invest? Here's a hot dividend share that could deliver a £2,653 passive income over just 3 years
I'm not just interested in high near-term dividend yields when I'm buying stocks for passive income. I want dividend shares that can provide a sustainably large and growing dividend over time. As this table shows, Greencoat UK (LSE:UKW) is expected to deliver impressively on both counts during the next few years: Year Dividend per share (forecast) Dividend yield 2025 10.38p 8.6% 2026 10.70p 8.8% 2027 11.01p 9.1% It's critical to remember that dividends are never, ever guaranteed. What's more, City forecasts (upon which these yields are based) can shoot both under and above. Yet, I'm confident this dividend star an deliver a long-lasting second income for investors. If projections are accurate, a £10,000 lump sum today will provide dividends of £2,653 between now and 2027 alone. Here's why I'm considering the FTSE 250 company for my own portfolio. Holding renewable energy stocks can be problematic at times. When the sun doesn't shine or the wind doesn't blow, profits can tumble as energy generation slumps, potentially impacting dividends. This is a constant threat for Greencoat UK, all of whose assets are located in Britain, as its name implies. However, this tighter geographic footprint also has its advantages. Britain is famed for its excellent wind speeds and long coastlines, and offshore wind capacity often exceeds 50%, making it one of the world's leading places to build turbines. Capacity on future wind farms is tipped to rise as high as 65%, too, as technology improves. The UK is also becoming one of the most supportive environments in the world for green energy. Just last Friday (4 July), the government announced new plans to turbocharge the onshore wind industry through steps like simplifying the planning process and boosting supply chains. In doing so, the government is looking to almost double total onshore wind capacity, to 27GW-29GW by 2030. This provides significant scope for Greencoat UK, which currently owns 49 wind farms, to keep its progressive payout policy going. As you can see, annual dividends here have risen consistently since it listed on the London Stock Exchange more than a decade ago. The only exception came in 2024, when the company cut its long-term energy generation forecasts by 2.4%, leading to a drop in asset values. But with these changes made, City analysts are expecting dividends to start chugging higher again from 2025. The graphic also underlines another attractive feature of renewable energy stocks like this. Electricity demand remains generally stable during all economic conditions, even during high inflation and pandemic-related downturns. So while these companies can keep producing the energy, the revenues and cash flows continue to steadily roll in. While it's not without risks, I'm considering adding Greencoat UK to my own portfolio for a long-term income. The post £10k to invest? Here's a hot dividend share that could deliver a £2,653 passive income over just 3 years appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Greencoat Uk Wind Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
